Innovative Small Molecule Inhibitors for Effective Treatment and Prevention of Coronavirus Infections
TS-066750 —
The ongoing COVID-19 pandemic, caused by the SARS-CoV-2 virus, has significantly impacted global health and economies. Despite vaccine efforts, issues such as vaccine hesitancy, delays in distribution, and emerging variants have highlighted the need for effective therapeutic interventions. These i…
- College: College
of
Veterinary
Medicine
- Inventors: Sharma, Amit; Li, Pui-Kai "Tom"; Xing, Enming
- Licensing Officer: Willson, Christopher
CDP-choline a host-directed therapeutic for disease caused by SARS CoV-2 infection.
TS-064192 — The Need: The global impact of the SARS CoV-2 coronavirus has created an urgent need for innovative medical interventions to address the challenges posed by COVID-19. Despite the availability of vaccines, sub-optimal vaccine uptake and concerns about new virus variants necessitate additional medical…
- College: College
of
Veterinary
Medicine
- Inventors: Davis, Ian; Schelhorn, Jean
- Licensing Officer: Willson, Christopher
Introducing HexaPro VSV: A Breakthrough in COVID-19 Vaccine Technology
TS-064191 —
The emergence of SARS-CoV-2 variants poses a significant challenge to existing COVID-19 vaccines, necessitating the development of a more durable and broadly protective solution. Current vaccines show reduced efficacy over time and struggle against Variants of Concern (VoCs) such as Omicron. Addre…
- College: College
of
Veterinary
Medicine
- Inventors: Li, Jianrong; Chamblee, Michelle; Lu, Mijia; Zhang, Yuexiu
- Licensing Officer: Willson, Christopher
A next generation intranasal trivalent Measles, Mumps and Covid vaccine
TS-064189 — The Need
The current global landscape demands innovative solutions to address the urgent need for a safe and efficacious SARS-CoV-2 vaccine, particularly for the vulnerable population of infants and children under 12 years old. Existing vaccines face challenges in terms of durability, cost, and sta…
- College: College
of
Veterinary
Medicine
- Inventors: Li, Jianrong; Xu, Jiayu; Zhang, Yuexiu
- Licensing Officer: Willson, Christopher
Live Attenuated Mumps Virus-Based SARS-CoV-2 Vaccines for Infants and Children
TS-062231 — The Need: Addressing the Urgent Need for a Safe and Effective SARS-CoV-2 Vaccine for Infants and Children
The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has brought about significant economic, emotional, and public health challenges worldwide. The pressing dema…
- College: College
of
Veterinary
Medicine
- Inventors: Li, Jianrong; Boyaka, Prosper; Lu, Mijia; Zhang, Yuexiu
- Licensing Officer: Willson, Christopher
Novel method for attenuating live vaccine candidates for non-segmented negative-sense RNA viruses
TS-062213 — The Need: Preventing Respiratory Syncytial Virus (RSV) Infection and Disease
Respiratory Syncytial Virus (RSV) is a highly prevalent and dangerous pathogen responsible for significant morbidity and mortality, particularly in infants, young children, and immunocompromised individuals. Despite its gl…
- College: College
of
Veterinary
Medicine
- Inventors: Li, Jianrong; He, Chuan; Lu, Mijia; Niewiesk, Stefan; Peeples, Mark; Xue, Miaoge; Zhang, Zijie; Zhao, Boxuan
- Licensing Officer: Willson, Christopher
Novel Live Attenuated Vaccines for Pneumoviruses
TS-037753 — A method to create vaccines for pneumoviruses, using recombinant viruses.
The Need
Pneumoviruses consist of pathogens that target the upper respiratory tract within their specific hosts. These include many important human and animal pathogens, such as human respiratory syncytial virus (hRSV), hMPV, bovine RSV, pneumonia virus of mice (PVM), and avian metapneumovirus (aMP…
- College: College
of
Veterinary
Medicine
- Inventors: Li, Jianrong; Cai, Hui; Peeples, Mark; Wang, Rongzhang
- Licensing Officer: Willson, Christopher
Novel Vaccine for Respiratory Syncytial Virus
TS-037299 — Recombinant vesicular stomatitis virus (rVSV) vaccines to fight against respiratory syncytial virus (RSV) infections.
The Need: Respiratory Syncytial Virus (RSV) is a major cause of infant hospitalization due to acute lower respiratory tract infections (ALRI) in children under 5 years of age globally, causing up to 200,000 deaths annually. RSV leads to significantly more hospitalizations than influenza in children …
- College: College
of
Veterinary
Medicine
- Inventors: Niewiesk, Stefan; Binjawadagi, Basavaraj; Li, Jianrong; Peeples, Mark
- Licensing Officer: Willson, Christopher
Novel Therapeutic for Influenza-Induced Acute Respiratory Distress Syndrome
TS-032198 — A parenteral administration
of a naturally occurring chemical used to treat influenza-induced hypoxemia, lung dysfunction, and acute respiratory distress syndrome (ARDS). This treatment could also be potentially useful in treating ARDS from other causes.
Acute respiratory distress syndrome (ARDS) is a clinical syndrome characterized by impaired alveolar gas exchange, a symptom that leads to a lack of oxygen in the bloodstream. This lack of oxygen to vital organs can lead to organ failure and results in a high possibility of patient death. The infl…
- College: College
of
Veterinary
Medicine
- Inventors: Davis, Ian
- Licensing Officer: Willson, Christopher
Improved Mucosal Immune Response During Vaccination
TS-015239 — Enhancing the mucosal (IgA) immune response by transiently blocking a specific cellular subset during vaccination.
The Need: Enhancing Mucosal Immune Response for Effective Vaccination
Infectious agents primarily invade the body through mucosal tissues, necessitating a robust immune response at these vulnerable sites. However, conventional vaccines often fail to induce sufficient immunoglobulin-A (IgA) antibodi…
- College: College
of
Veterinary
Medicine
- Inventors: Boyaka, Prosper
- Licensing Officer: Willson, Christopher